Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven P Rowe

Showing results (421-430 of 504) with videos related to

Pageof 51
Sort By:
Prostate Cancer and Prostatic Diseases|October 16, 2019
A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancerAshley E Ross, Paula J Hurley, Phuoc T Tran, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 14, 2017
Predictive Value of <sup>18</sup>F-FDG PET in Patients with Advanced Medullary Thyroid Carcinoma Treated with VandetanibRudolf A Werner, Jan-Stefan Schmid, Takahiro Higuchi, et al.
Nuclear Medicine Communications|February 22, 2023
Wnt/β-catenin modulating drugs regulate somatostatin receptor expression and internalization of radiolabelled octreotide in neuroendocrine tumor cellsAlexander Weich, Dorothea Rogoll, Melissa Peschka, et al.
Annals of Nuclear Medicine|October 26, 2017
Low levels of PSMA expression limit the utility of <sup>18</sup>F-DCFPyL PET/CT for imaging urothelial carcinomaScott P Campbell, Alexander S Baras, Mark W Ball, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 17, 2018
Imaging of Nonprostate Cancers Using PSMA-Targeted Radiotracers: Rationale, Current State of the Field, and a Call to ArmsRoberto A Salas Fragomeni, Tali Amir, Sara Sheikhbahaei, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 28, 2019
Prospective Comparison of PET Imaging with PSMA-Targeted <sup>18</sup>F-DCFPyL Versus Na<sup>18</sup>F for Bone Lesion Detection in Patients with Metastatic Prostate CancerSteven P Rowe, Xin Li, Bruce J Trock, et al.
BJU International|September 23, 2024
The use of <sup>99m</sup>Tc-tetrofosmin in the characterisation of indeterminate renal masses: a pilot studyErgi Spiro, Salikh Murtazaliev, Alireza Amindarolzarbi, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 3, 2017
Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imagingSara Sheikhbahaei, Ali Afshar-Oromieh, Matthias Eiber, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 7, 2024
Prognostic Performance of RECIP 1.0 Based on [<sup>18</sup>F]PSMA-1007 PET in Prostate Cancer Patients Treated with [<sup>177</sup>Lu]Lu-PSMA I&TPhilipp E Hartrampf, Thomas Hüttmann, Anna Katharina Seitz, et al.
Clinical Nuclear Medicine|February 15, 2019
Novel Functional Renal PET Imaging With 18F-FDS in Human SubjectsRudolf A Werner, Alvaro A Ordonez, Julian Sanchez-Bautista, et al.
Pageof 51

Showing results (421-430 of 504) with videos related to

Sort By:
Pageof 51
Prostate Cancer and Prostatic Diseases|October 16, 2019
A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancerAshley E Ross, Paula J Hurley, Phuoc T Tran, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 14, 2017
Predictive Value of <sup>18</sup>F-FDG PET in Patients with Advanced Medullary Thyroid Carcinoma Treated with VandetanibRudolf A Werner, Jan-Stefan Schmid, Takahiro Higuchi, et al.
Nuclear Medicine Communications|February 22, 2023
Wnt/β-catenin modulating drugs regulate somatostatin receptor expression and internalization of radiolabelled octreotide in neuroendocrine tumor cellsAlexander Weich, Dorothea Rogoll, Melissa Peschka, et al.
Annals of Nuclear Medicine|October 26, 2017
Low levels of PSMA expression limit the utility of <sup>18</sup>F-DCFPyL PET/CT for imaging urothelial carcinomaScott P Campbell, Alexander S Baras, Mark W Ball, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 17, 2018
Imaging of Nonprostate Cancers Using PSMA-Targeted Radiotracers: Rationale, Current State of the Field, and a Call to ArmsRoberto A Salas Fragomeni, Tali Amir, Sara Sheikhbahaei, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 28, 2019
Prospective Comparison of PET Imaging with PSMA-Targeted <sup>18</sup>F-DCFPyL Versus Na<sup>18</sup>F for Bone Lesion Detection in Patients with Metastatic Prostate CancerSteven P Rowe, Xin Li, Bruce J Trock, et al.
BJU International|September 23, 2024
The use of <sup>99m</sup>Tc-tetrofosmin in the characterisation of indeterminate renal masses: a pilot studyErgi Spiro, Salikh Murtazaliev, Alireza Amindarolzarbi, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 3, 2017
Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imagingSara Sheikhbahaei, Ali Afshar-Oromieh, Matthias Eiber, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 7, 2024
Prognostic Performance of RECIP 1.0 Based on [<sup>18</sup>F]PSMA-1007 PET in Prostate Cancer Patients Treated with [<sup>177</sup>Lu]Lu-PSMA I&TPhilipp E Hartrampf, Thomas Hüttmann, Anna Katharina Seitz, et al.
Clinical Nuclear Medicine|February 15, 2019
Novel Functional Renal PET Imaging With 18F-FDS in Human SubjectsRudolf A Werner, Alvaro A Ordonez, Julian Sanchez-Bautista, et al.
Pageof 51